BioMarins Gene Therapy for Hemophilia A Continues to Impress – Rare Disease Report (blog)
Rare Disease Report (blog) |
BioMarins Gene Therapy for Hemophilia A Continues to Impress
Rare Disease Report (blog) FDA has granted Breakthrough Therapy Designation to Biomarin’s gene therapy for hemophilia A, valoctocogene roxaparvovec (BMN 270). BioMarin Announces Third Quarter 2017 Financial ResultsPR Newswire (press release) |
KABC-TV |
New CAR–T cell therapy offers hope to lymphoma patients
KABC-TV Forman told Fata about new research they were doing at City of Hope, called CAR–T cell therapy. Doctors harvested his T cells, ramped them up, then sent them back into his body. “Their sole purpose, the way we’ve engineered them, is to go into the body … |
Express.co.uk |
Dementia CURE? UK charity ‘welcomes’ stem cell treatment research
Express.co.uk Its comments came after scientists revealed stem cells were needed to replace neurones that have been lost in dementia patients. The cells – which can be moulded by scientists to become any type of cell in the body – also help to revitalise stressed … |
Express.co.uk |
Dementia CURE? UK charity ‘welcomes’ stem cell treatment research
Express.co.uk Its comments came after scientists revealed stem cells were needed to replace neurones that have been lost in dementia patients. The cells – which can be moulded by scientists to become any type of cell in the body – also help to revitalise stressed … |
|
Dstl details synthetic biology armour progress
IHS Jane’s 360 The UK’s Defence and Science Technology Laboratory (Dstl) synthetic biology (SynthBio) armour programme is at Technology Readiness Level 3, with samples currently able to undergo hardness testing, Dstl representatives have told Jane’s . They also … |